TY - JOUR
T1 - Making medicines baby size
T2 - The challenges in bridging the formulation gap in neonatal medicine
AU - O’Brien, Fiona
AU - Clapham, David
AU - Krysiak, Kamelia
AU - Batchelor, Hannah
AU - Field, Peter
AU - Caivano, Grazia
AU - Pertile, Marisa
AU - Nunn, Anthony
AU - Tuleu, Catherine
PY - 2019/5/31
Y1 - 2019/5/31
N2 - The development of age-Appropriate formulations should focus on dosage forms that can deliver variable yet accurate doses that are safe and acceptable to the child, are matched to his/her development and ability, and avoid medication errors. However, in the past decade, the medication needs of neonates have largely been neglected. The aim of this review is to expand on what differentiates the needs of preterm and term neonates from those of the older paediatric subsets, in terms of environment of care, ability to measure and administer the dose (from the perspective of the patient and carer, the routes of administration, the device and the product), neonatal bio-Pharmaceutics and regulatory challenges. This review offers insight into those challenges posed by the formulation of medicinal products for neonatal patients in order to support the development of clinically relevant products.
AB - The development of age-Appropriate formulations should focus on dosage forms that can deliver variable yet accurate doses that are safe and acceptable to the child, are matched to his/her development and ability, and avoid medication errors. However, in the past decade, the medication needs of neonates have largely been neglected. The aim of this review is to expand on what differentiates the needs of preterm and term neonates from those of the older paediatric subsets, in terms of environment of care, ability to measure and administer the dose (from the perspective of the patient and carer, the routes of administration, the device and the product), neonatal bio-Pharmaceutics and regulatory challenges. This review offers insight into those challenges posed by the formulation of medicinal products for neonatal patients in order to support the development of clinically relevant products.
KW - biopharmaceutics
KW - dosage form
KW - excipient
KW - formulation
KW - formulation development
KW - Neonates
KW - NICU
U2 - 10.3390/ijms20112688
DO - 10.3390/ijms20112688
M3 - Review article
C2 - 31159216
AN - SCOPUS:85067173943
SN - 1661-6596
VL - 20
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 11
M1 - 2688
ER -